Abstract
Purposeless chewing in rats was dose dependently increased by acute administration of the dopamine D-1 receptor agonist SKF 38393 (5–20 mg/kg), the D-2 receptor antagonist sulpiride (10–100 mg/kg) and the D-2 receptor agonist quinpirole (0.05–0.25 mg/kg). Only high doses of the D-1 receptor antagonist SCH 23390 (1 and 5 mg/kg) induced purposeless chewing. SCH 23390 (0.05 mg/kg) blocked SKF 38393 (20 mg/kg)-induced purposeless chewing, but had no effect on the purposeless chewing induced by sulpiride (100 mg/kg) or quinpirole (0.1 mg/kg). A dose of SKF 38393 (5 mg/kg) which did not itself induce chewing, potentiated the increase in purposeless chewing observed after administration of sulpiride (100 mg/kg). Administration of SKF 38393 (20 mg/kg) and quinpirole (0.1 mg/kg) did not induce purposeless chewing but stereotyped licking was observed. Administration of sulpiride (100 mg/kg) with quinpirole (0.1 mg/kg) produced an incidence of purposeless chewing not different from that observed when either compound was administered alone. Acute administration of the cholinergic agonist pilocarpine (0.5–4.0 mg/kg) or the cholinesterase inhibitor physostigmine (0.05–0.2 mg/kg) increased the frequency of purposeless chewing in rats. Co-administration of pilocarpine (0.5 mg/kg) with sulpiride (100 mg/kg) increased the frequency of purposeless chewing above that seen when either compound was administered alone. Co-administration of pilocarpine (0.5 mg/kg) with SKF 38393 (20 mg/kg) increased the frequency of purposeless chewing in an additive manner. Co-administration of physostigmine (0.1 mg/kg) with sulpiride (100 mg/kg) but not SKF 38393 (20 mg/kg), increased the frequency of purposeless chewing above that observed when either compound was administered alone. Quinpirole (0.1 mg/kg)-induced purposeless chewing was not affected by co-administration with either pilocarpine (0.5 mg/kg) or physostigmine (0.1 mg/kg). The anticholinergic agent scopolamine (0.1 mg/kg) blocked the purposeless chewing induced by either SKF 38393 (20 mg/kg) or sulpiride (100 mg/kg), but had no effect on the purposeless chewing induced by quinpirole (0.1 mg/kg). Contrary to previous reports, acute manipulation of D-1 or D-2 receptor function can both enhance purposeless chewing behaviour in rats. These apparently identical behaviours can be differentiated by the response to cholinergic manipulation.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Andersen PH (1988) Comparison of the pharmacological characteristics of [3H] raclopride and [3H]SCH 23390 binding to dopamine receptors in vivo in mouse brain. Eur J Pharmacol 146:113–120
Arnt J, Hyttel J (1986) Inhibition of SKF 38393- and pergolide-induced circling in rats with unilateral 6-OHDA lesion is correlated to dopamine D-1 and D-2 receptor affinities in vitro. J Neural Transm 67:225–240
Arnt J, Hyttel J, Bach-Lauriten T (1986) Further studies of the mechanism behind scopolamine-induced reversal of antistereotypic and cataleptogenic effects of neuroleptics in rats. Acta Pharmacol Toxicol 59:319–324
Arnt J, Hyttel J, Perregaard J (1987) Dopamine D-1 receptor agonists combined with the selective D-2 agonist quinpirole facilitate the expression of oral stereotyped bebehaviour in rats. Eur J Pharmacol 133:137–145
Bischoff S, Heinrich M, Sonntag JM, Krauss J (1986) The D-1 dopamine receptor antagonist SCH 23390 also interacts potently with brain serotonin (5HT-2) receptors. Eur J Pharmacol 129:367–370
Braun AR, Chase TN (1986) Obligatory D-1/D-2 receptor interactions in the generation of dopamine agonist related behaviours. Eur J Pharmacol 131:301–306
Clow A, Theodorou A, Jenner P, Marsden CD (1980) Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration. Eur J Pharmacol 63:145–157
Consolo S, Wu CF, Fusi R (1987) D-1 receptor-linked mechanism modulates cholinergic neurotransmission in rat striatum. J Pharmacol Exp Ther 242:300–305
Fage D, Scatton B (1986) Opposing effects of D-1 and D-2 receptor antagonists on acetylcholine levels in the rat striatum. Eur J Pharmacol 129:359–362
Gorell JM, Czarnecki B, Hubbell S (1986) Functional antagonism of D-1 and D-2 dopaminergic mechanisms affecting striatal acetylcholine release. Life Sci 38:2247–2254
Hicks PE, Schoemaker H, Langer SZ (1984) 5HT-receptor antagonist properties of SCH 23390 in vascular smooth muscle and brain. Eur J Pharmacol 105:339–342
Hyttel J (1983) SCH 23390 — the first selective dopamine D-1 antagonist. Eur J Pharmacol 91:153–154
Johansson P, Levin ED, Gunne LM, Ellisson GD (1987) Opposite effects of a D-1 and a D-2 agonist on oral movements in rats. Eur J Pharmacol 134:83–88
Levy AD, See RE, Levin ED, Ellison GD (1987) Neuroleptic induced oral movements in rats: methodological issues. Life Sci 41:1499–1506
Longoni R, Spina L, Di Chiara G (1987) Permissive role of D-1 receptor stimulation by endogenous dopamine for the expression of postsynaptic D-2 mediated behavioural responses. Yawning in rats. Eur J Pharmacol 134:163–173
McGonicle P, Boyson SJ, Reuter S, Molinoff PB (1989) Effects of chronic treatment with selective and non-selective antagonists on the subtypes of dopamine receptors. Synapse 3:74–82
Murray AM, Waddington JL (1989a) The induction of grooming and vacuous chewing by a series of selective D-1 dopamine receptor agonists: two directions of D-1: D-2 interaction. Eur J Pharmacol 160:377–384
Murray AM, Waddington JL (1989b) Further evidence for two directions of D-1: D-2 dopamine receptor interaction revealed concurrently in distinct elements of typical and atypical behaviour: studies with the new enantioselective D-2 agonist LY 163502. Psychopharmacology 98:245–250
Ogren SO, Fuxe K (1988) D-1 and D-2 receptor-antagonist induce catalepsy via different efferent striatal pathways. Neurosci Lett 85:333–338
Rosengarten H, Schweitzer JW, Friedhoff AJ (1983) Induction of oral dyskinesias in naive rats by D-1 stimulation. Life Sci 33:2479–2482
Rupniak NMJ, Jenner P, Marsden CD (1983) Cholinergic manipulation of perioral behaviour induced by chronic neuroleptic administration to rats. Psychopharmacology 79:226–230
Rupniak NMJ, Jenner P, Marsden CD (1985) Pharmacological characterisation of spontaneous or drug-associated purpose-less chewing movements in rats. Psychopharmacology 85:71–79
Salamone JD, Lalies ND, Channell FL, Iversen SD (1986) Behavioural and pharmacological characterization of the mouth movements induced by muscarinic agonists in the rat. Psychopharmacology 88:467–471
Skarsfeldt T, Larsen J-J (1988) SCH 23390 — a selective D-1 receptor antagonist with putative 5HT-1 receptor agonistic activity. Eur J Pharmacol 148:389–395
Stewart BR, Jenner P, Marsden CD (1988) The pharmacological characterisation of pilocarpine-induced purposeless chewing behaviour in the rat. Psychopharmacology 96:55–62
Stewart BR, Jenner P, Marsden CD (1989) Induction of purposeless chewing behaviour in rats by 5HT agonist drugs. Eur J Pharmacol 162:101–107
Stoessl AJ, Dourish CT, Iversen SD (1989) Chronic neuroleptic-induced mouth movements in the rat: suppression by CCK and selective dopamine D-1 and D-2 receptor antagonists. Psychopharmacology 98:372–379
Undie A, Friedman E (1988) Differences in the cataleptic actions of SCH 23390 and selected neuroleptics. Psychopharmacology 96:311–316
Waddington JL, Cross AJ, Gamble SJ, Bourne RC (1983) Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment. Science 220:530–532
Zetterstrom T, Sharp T, Ungerstedt U (1985) Effect of neuroleptic drugs on striatal dopamine release and metabolism in the awake rat studied by intracerebral dialysis Eur J Pharmacol 106:27–37
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Collins, P., Broekkamp, C.L.E., Jenner, P. et al. Drugs acting at D-1 and D-2 dopamine receptors induce identical purposeless chewing in rats which can be differentiated by cholinergic manipulation. Psychopharmacology 103, 503–512 (1991). https://doi.org/10.1007/BF02244250
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02244250